Literature DB >> 7543193

Panretinal cryopexy for the management of neovascularization of the iris.

M Stefaniotou1, C A Paschides, K Psilas.   

Abstract

Panretinal cryopexy was used for the treatment of 15 eyes with neovascularization of the anterior segment, treated with panretinal photocoagulation in the past. The eyes were classified preoperatively according to grade of neovascularization of the iris and anterior chamber angle using Weiss' and Gold's device system. Four eyes had rubeosis iridis with normal intraocular pressure and 11 had neovascular glaucoma. Rubeosis was secondary to proliferative diabetic retinopathy and/or central retinal vein occlusion. Nine eyes with grade 0, I and II neovascularization showed regression of neovascularization and controlled intraocular pressure. Six eyes with grade IV showed regression of neovascularization but uncontrolled intraocular pressure. All those eyes presented extensive peripheral anterior synechias.

Entities:  

Mesh:

Year:  1995        PMID: 7543193     DOI: 10.1159/000310600

Source DB:  PubMed          Journal:  Ophthalmologica        ISSN: 0030-3755            Impact factor:   3.250


  4 in total

1.  Evaluation of the blood-aqueous barrier by laser flare cell photometry following retinal cryocoagulation.

Authors:  Nicole Eter; Manfred Spitznas; Zaher Sbeity; Antje Vogel
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2003-12-05       Impact factor: 3.117

2.  Important Risk Factors Were Not Included.

Authors:  Dieter Schmidt
Journal:  Dtsch Arztebl Int       Date:  2017-04-21       Impact factor: 5.594

3.  The Ahmed glaucoma valve in neovascular glaucoma (An AOS Thesis).

Authors:  Peter A Netland
Journal:  Trans Am Ophthalmol Soc       Date:  2009-12

4.  Panretinal photocoagulation with simultaneous cryoretinopexy or intravitreal bevacizumab for neovascular glaucoma.

Authors:  Tomoaki Tatsumi; Shuichi Yamamoto; Juntaro Uehara; Takeshi Sugawara; Takayuki Baba; Masayuki Inoue; Hiroko Hata; Yoshinori Mitamura
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2012-12-19       Impact factor: 3.117

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.